Dr. Sahin is an experienced cancer biologist with a strong background in cancer biology, functional genomics, bioinformatics, and drug discovery. He discovered the roles of many proteins and non-coding RNAs in the pathogenesis of drug resistant and metastatic cancers. Dr. Sahin is currently a Professor and Endowed Chair in the Department of Biochemistry & Molecular Biology at Medical University of South Carolina (MUSC), Charleston, SC. He is also the Program Director for Basic Science Translation and the Co-leader of the Breast Transdisciplinary Cancer Team (TcT) at NCI-designated MUCS Hollings Cancer Center. Previously, he served as Research Team Leader at German Cancer Research Center (DKFZ), Research Faculty in the Department of Molecular & Cellular Oncology at the University of Texas MD Anderson Cancer Center (MDACC), Assistant Professor in the Department of Molecular Biology & Genetics at Bilkent University and Associate Professor in the Department of Drug Discovery & Biomedical Sciences at the University of South Carolina. To date, Dr. Sahin published more than 80 peer-reviewed papers in the field of cancer research/drug discovery in high impact international journals and filed multiple patent applications. He is also co-founder and manager of OncoCube Therapeutics and a member of the scientific advisory board of A2A Pharmaceuticals.

Email: sahin@loxigen.com